Antibodies against Chlamydia trachomatis and ovarian cancer risk in two independent populations by Trabert, B, Waterboer, T, Idahl, A, Brenner, N, Brinton, L, Butt, J, Coburn, S, Hartge, P, Hufnagel, K, Inturrisi, F, Lissowska, J, Mentzer, A, Peplonska, B, Sherman, M, Wills, G, Woodhall, S, Pawlita, M, Wentzensen, N

“…<br/><strong>Results: </strong>In the Polish study, antibodies (based on laboratory cut-point) against the chlamydia plasmid-encoded Pgp3 protein (serological gold standard) were associated with increased ovarian cancer risk (adjusted odds ratio [OR] ¼ 1.63, 95% confidence interval [CI] ¼ 1.20 to 2.22); when a positive result was redefined at higher levels, ovarian cancer risk was increased (cut-point 2: OR ¼ 2.00, 95% CI ¼ 1.38 to 2.89; cut-point 3 [max OR]: OR ¼ 2.19, 95% CI ¼ 1.29 to 3.73). …”